Agilent Technologies, Inc. $A Shares Sold by Vaughan Nelson Investment Management L.P.

Key Points

• Vaughan Nelson Investment Management L.P. reduced its holdings in Agilent Technologies by 2.2%, selling 3,248 shares during the second quarter, but still owns approximately $17.16 million worth of the company's stock.
• Analysts have set new price targets for Agilent Technologies, with Wells Fargo raising their target from $140.00 to $150.00, while Barclays also increased theirs to $150.00, indicating a positive outlook.
• Agilent Technologies announced a quarterly dividend of $0.248 per share, which is set to be paid on October 22nd, representing a 0.7% dividend yield and a payout ratio of 23.24%.

Vaughan Nelson Investment Management L.P. cut its holdings in Agilent Technologies, Inc. (NYSE:A - Free Report) by 2.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 145,392 shares of the medical research company's stock after selling 3,248 shares during the period. Vaughan Nelson Investment Management L.P. owned 0.05% of Agilent Technologies worth $17,158,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Agilent Technologies by 0.7% during the first quarter. Vanguard Group Inc. now owns 33,408,626 shares of the medical research company's stock worth $3,908,141,000 after purchasing an additional 240,965 shares in the last quarter. Pictet Asset Management Holding SA lifted its stake in Agilent Technologies by 2.5% during the first quarter. Pictet Asset Management Holding SA now owns 5,341,870 shares of the medical research company's stock worth $624,888,000 after purchasing an additional 128,131 shares in the last quarter. Generation Investment Management LLP lifted its stake in Agilent Technologies by 19.8% during the first quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company's stock worth $582,976,000 after purchasing an additional 824,243 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Agilent Technologies by 18.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,836,105 shares of the medical research company's stock worth $448,748,000 after purchasing an additional 604,124 shares in the last quarter. Finally, Impax Asset Management Group plc lifted its stake in Agilent Technologies by 3.6% during the first quarter. Impax Asset Management Group plc now owns 2,931,794 shares of the medical research company's stock worth $342,961,000 after purchasing an additional 102,365 shares in the last quarter.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Wells Fargo & Company upped their price target on Agilent Technologies from $140.00 to $150.00 and gave the stock an "overweight" rating in a research note on Monday, September 15th. Robert W. Baird upped their price objective on Agilent Technologies from $141.00 to $142.00 and gave the stock an "outperform" rating in a research report on Thursday, August 28th. Evercore ISI reduced their price objective on Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating on the stock in a research note on Thursday, August 28th. Weiss Ratings restated a "hold (c)" rating on shares of Agilent Technologies in a report on Saturday, September 27th. Finally, Barclays increased their price target on Agilent Technologies from $125.00 to $150.00 and gave the company an "equal weight" rating in a research report on Thursday. Six investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $142.17.

Agilent Technologies Stock Performance

NYSE:A opened at $141.91 on Friday. The firm has a market capitalization of $40.23 billion, a PE ratio of 33.31, a price-to-earnings-growth ratio of 4.62 and a beta of 1.26. The business's fifty day moving average price is $122.80 and its 200 day moving average price is $116.37. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $153.84.

Agilent Technologies (NYSE:A - Get Free Report) last posted its earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, meeting the consensus estimate of $1.37. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.Agilent Technologies's revenue for the quarter was up 10.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, sell-side analysts anticipate that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 22nd. Shareholders of record on Tuesday, September 30th will be issued a dividend of $0.248 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.99 annualized dividend and a dividend yield of 0.7%. Agilent Technologies's dividend payout ratio (DPR) is presently 23.24%.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.